{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104602","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.954814+00:00","generated_at":"2026-05-17T18:01:14.613224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025","bullets":["Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.","Cash, equivalents and marketable securities $224.9M as of June 30, 2025; expected to fund operations into mid-2027.","Phase 2 Avail trial of canvuparatide in hypoparathyroidism topline results expected in Q3 2025.","Phase 2a trial of imapextide (post-bariatric hypoglycemia) and Phase 1 trial of MBX 4291 (obesity) to initiate in Q3 2025.","Appointed Dr. Andreas Moraitis as SVP of Clinical Development in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104602","json":"https://secwatch.observer/filing/0000950170-25-104602.json","markdown":"https://secwatch.observer/filing/0000950170-25-104602.md","text":"https://secwatch.observer/filing/0000950170-25-104602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/0000950170-25-104602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/mbx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:01:14.613224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}